<DOC>
	<DOCNO>NCT01397786</DOCNO>
	<brief_summary>The purpose study ass long-term safety , tolerability efficacy oral OPC-34712 monotherapy adult schizophrenia .</brief_summary>
	<brief_title>Safety Tolerability Study Oral OPC-34712 Maintenance Treatment Adults With Schizophrenia</brief_title>
	<detailed_description>Schizophrenia severely debilitate mental illness affect approximately 1 % world population . Hallucinations delusion strike characteristic positive symptom schizophrenia ; however , subtle negative symptom ( eg , social withdrawal lack emotion , energy , motivation ) may also present . The first antipsychotic develop treatment schizophrenia effective positive symptom , show little efficacy negative symptom also associate high incidence side effect . Second generation antipsychotic , represent significant advancement treatment psychotic disorder effective time exhibit few side effect first generation antipsychotic . Although generally safer first generation antipsychotic , second-generation antipsychotic devoid undesirable side effect Hyperprolactinemia weight gain . In addition , safety drug vary considerably .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Male female subject 18 65 year age , diagnosis schizophrenia , define DSMIVTR criterion 2 . Outpatient status last visit Trial 33110230 Trial 33110231 3 . Willing discontinue prohibitive psychotropic medication meet protocol require washout prior trial period . 4 . Other protocol specific inclusion criterion may apply . 1 . Females breastfeed and/or positive pregnancy test result prior receive study drug 2 . Subjects current DSMIVTR Axis I diagnosis : Schizoaffective disorder MDD Bipolar disorder Delirium , dementia , amnestic cognitive disorder Borderline , paranoid , histrionic , schizotypal , schizoid antisocial personality disorder 3 . Subjects present first episode schizophrenia 4 . Other protocol specific exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>